For cardiovascular outcomes, the SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared with placebo (HR 0.74, 95% CI 0.58 to 0.95, P=0.02) over 2.1 years [9]
Adjustments for Individual Response and Tolerance Not everyone responds to semaglutide in the same way
Why should I choose an injection over an OTC supplement
The effective cost per therapeutic dose likely favors injection when bioavailability discounting is applied
Sign up for our newsletter, The Selection, and shop smarter
8 Conclusions This study highlights the significance of exosomes in cancer-related processes, drug resistance, and potential therapeutic applications